• Users Online: 3897
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 8  |  Issue : 1  |  Page : 87-91

Interim analysis report of kuanxiong aerosol in improving angina and quality of life after percutaneous coronary intervention


1 The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China
2 Department of Cardiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
3 Department of Cardiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Postdoctoral Research Station, Institute of Integrative Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China

Correspondence Address:
Prof, Dan-Ping Xu
Department of Cardiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120; Postdoctoral Research Station, Institute of Integrative Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/wjtcm.wjtcm_26_21

Rights and Permissions

Objective: The objective is to observe the effect of Kuanxiong aerosol (KXA) on angina and the quality of life of patients after percutaneous coronary intervention (PCI). Materials and Methods: Six hundred patients with angina after PCI (AAP) were randomly assigned to an experimental group and a control group (n = 300 in each group) and received basic treatment with KXA or basic treatment (respectively) for 8 weeks. The Seattle Angina Questionnaire (SAQ) and visual analog scale (VAS) scores of the two groups during the screening period and five follow-up periods were compared. Results: A total of 179 patients were included in this interim report, including 85 in the experimental group and 94 in the control group. Among the five-dimensional scores of the SAQ, the improvement in the angina frequency and quality of life scores in the experimental group was better than those in the control group after treatment (P < 0.01), and the difference in scores of the remaining dimensions was not statistically significant (P > 0.01). The difference in VAS scores between the two groups was not statistically significant (P > 0.01). No obvious adverse reactions were observed between the two groups. Conclusions: KXA can reduce the frequency of AAP and improve patients' quality of life.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed648    
    Printed22    
    Emailed0    
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal